ArticleTechnology in cancer research & treatment
Combined DNA-PK and PARP Inhibition as a Therapeutic Strategy in BRCA-Mutated Prostate Cancer: An in Vitro Pilot Study.
Thomas Paul Scherer et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.